CV Sciences, Inc. Engages ICR to Enhance Investor Relations and Corporate Communications
LAS VEGAS, Feb. 05, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp CBD products through its industry-dominating brand PlusCBD Oil™, today announced that it has engaged ICR, a leading strategic communications and advisory firm, to enhance the Company’s investor relations, media relations and corporate communications program.
“CV Sciences experienced significant growth in 2018 and we are well positioned to continue to accelerate our growth in 2019 and beyond as we execute our business strategy, expand our retail and e-commerce distribution, and bring innovative branded CBD products to market,” said Joseph Dowling, Chief Executive Officer. “ICR’s capital markets and financial media expertise, combined with its significant experience in the nutritional supplement, cannabis, CPG and retail sectors will enhance our communications to all of our stakeholders, broaden exposure to institutional investors, and deepen the financial communities’ understanding of CV Sciences’ differentiated business model, growth strategy and market opportunity. We are excited to partner with ICR as we enter this next chapter of growth for our Company and the hemp-based CBD market.”
CV Sciences’ PlusCBD Oil™ is the top-selling brand of hemp-derived CBD on the market and ranked second in sales in the independent natural products retailer channel when combining all product category sales in food supplements, according to SPINS, the leading provider of data and insights for the natural, organic and specialty products industry. The Company’s natural product retail channel includes more than 2,000 locations nationwide and the Company expects the passage of the 2018 Farm Bill to result in significantly increased distribution across food, drug and mass (FDM) channel retailers, broadening exposure and availability of PlusCBD Oil to millions of U.S. consumers.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD. The Company’s Plus CBD Oil™ is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
About ICR
Established in 1998, ICR partners with companies to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm’s highly-differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to more than 650 clients in approximately 20 industries. ICR’s healthcare practice operates under the Westwicke brand (www.westwicke.com). Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America, maintaining offices in New York, Norwalk, Boston, Baltimore, San Francisco, San Diego and Beijing. ICR also advises on capital markets transactions through ICR Capital, LLC. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT INFORMATION:
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
scott.vanwinkle@icrinc.com
Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com
Released February 5, 2019